Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas

This article was originally published in The Pink Sheet Daily

Executive Summary

Already holding worldwide rights to the oral formulation and rest-of-world rights to intravenous vernakalant, Merck will partner with Cardiome Pharma to obtain FDA approval of IV vernakalant.

You may also be interested in...



Deals Of The Week: Roche/Galaxy, Mallinckrodt/CNS Therapies, Valeant/QLT

Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.

Merck Drops Development Of Cardiome’s Oral Vernakalant

Higher regulatory hurdles for anti-arrhythmic drugs have pushed Merck to discontinue the development of Cardiome’s oral vernakalant.

Sanofi Halts Multaq Trial Early Due To Cardiac Events

The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel